(Press-News.org) A drug used to treat type 2 diabetes may also be effective in slowing the progression of prostate cancer. This is shown by an international study in which researchers at Umeå University, Sweden, have participated. The researchers have found that drugs that regulate a particular protein have a key role in reducing prostate cancer recurrence among diabetic patients.
"This is a significant discovery. For the first time, we have clinical observations showing that prostate cancer patients with diabetes who received drugs targeting the protein remained relapse-free during the period we followed them," says Lukas Kenner, visiting professor at Umeå University and one of the study's lead authors.
The protein that the researchers have studied is called PPARy, peroxisome proliferator-activated receptor gamma. In diabetes research, PPARy has been extensively studied in view of the protein's role in metabolic processes and insulin sensitivity.
What the research team, led by Professor Kenner, has now shown is that patients who were treated for prostate cancer and who also had diabetes, who were treated with drugs that regulate the PPARy protein, managed without recurrence of prostate cancer. In studies of cell cultures, researchers also observed that the drug in question, pioglitazone, not only inhibits the growth of prostate cancer cells but also drives a metabolic reprogramming of the cancer cells, weakening their ability to grow.
"The findings are very promising, but further clinical studies are needed to both confirm the results and to investigate whether the treatment can also be used in patients with prostate cancer who do not have diabetes," says Lukas Kenner.
The research has been conducted as a combination of studies on cells and mice as well as a retrospective study of 69 prostate cancer patients with type 2 diabetes that was followed by the Medical University of Innsbruck in 2014–2023.
In certain types of cancer, PPARγ can contribute to tumour growth or metabolic changes. The drug, pioglitazone, is a so-called agonist that binds to a PPARy receptor and activates it. Thereby it modulates the signalling pathway and aims to counteract tumour-promoting effects by changing the cellular metabolism but may also reduce inflammation.
The research group behind the study includes researchers in Austria, the Czech Republic, Germany, the United Kingdom, and Sweden.
END
Diabetes drug gives hope for new treatment for prostate cancer
2025-05-20
ELSE PRESS RELEASES FROM THIS DATE:
New US dementia cases in decline, but continued rise in people living with the condition
2025-05-20
New cases of dementia in the United States declined from 2015 to 2021, but the number of people living with the condition continued to rise due to population ageing, with nearly 2.9 million traditional Medicare beneficiaries (around 12%) living with a dementia diagnosis in 2021, finds a study published by The BMJ today.
What’s more, a greater burden of dementia was seen in marginalized and low resource communities, highlighting the importance of policy approaches to promote equitable dementia care, say the ...
Doctors group asks National Institutes of Health to investigate Arizona State University for research misconduct
2025-05-20
TEMPE, Ariz. — The Physicians Committee for Responsible Medicine filed a complaint with the National Institutes of Health’s Office of Laboratory Animal Welfare today, May 19, 2025, asking for an investigation of Arizona State University’s use of animals to study the effects of dietary supplements on adults with Down syndrome.
“Arizona State University cannot justify its use of mice to study a common nutrient that could be easily and ethically studied in consenting human volunteers,” the complaint says. “These uses of animals run afoul of the ...
St. Jude scientist Charles Mullighan elected to the Royal Society of London
2025-05-20
St. Jude Children’s Research Hospital leukemia researcher Charles G. Mullighan, MBBS (Hons), MSc, MD, senior deputy director of the St. Jude Comprehensive Cancer Center, has been elected as a Fellow of the Royal Society of London, the oldest scientific academy in continuous existence.
Mullighan was selected to join the Royal Society for his trailblazing contributions to genomic research, which have advanced the understanding, diagnosis and treatment of acute leukemia, notably childhood acute lymphoblastic leukemia ...
1.5°C Paris Climate Agreement target too high for polar ice sheets and sea level rise
2025-05-20
Efforts to limit the global temperature increase to 1.5°C under the Paris Climate Agreement may not go far enough to save the world’s ice sheets, according to a new study.
Research led by Durham University, UK, suggests the target should instead be closer to 1°C to avoid significant losses from the polar ice sheets and prevent a further acceleration in sea level rise.
The team reviewed a wealth of evidence to examine the effect that the 1.5°C target would have on the ice sheets in Greenland and Antarctica, which together store enough ice to raise global sea levels by almost 65 metres.
The mass of ice lost from these ice ...
Scientists discover potential new targets for Alzheimer’s drugs
2025-05-20
CAMBRIDGE, MA -- By combining information from many large datasets, MIT researchers have identified several new potential targets for treating or preventing Alzheimer’s disease.
The study revealed genes and cellular pathways that haven’t been linked to Alzheimer’s before, including one involved in DNA repair. Identifying new drug targets is critical because many of the Alzheimer’s drugs that have been developed to this point haven’t been as successful as hoped.
Working with researchers at Harvard Medical School, the team used data from humans and fruit flies to identify cellular pathways linked to neurodegeneration. ...
Scientists develop new treatment with potential to tackle commonest form of childhood cancer
2025-05-20
A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukaemia (B-ALL), the commonest cancer in childhood and one that can be particularly difficult to treat in older patients, according to Cambridge scientists.
Although the research has so far only been conducted in cell lines and mice, the team is seeking funding to begin clinical trials in patients shortly.
More than 500 people a year in the UK are diagnosed with B-ALL, many of whom are children, where it makes up 40% of all ...
Technique rapidly measures cells’ density, reflecting health and developmental state
2025-05-20
CAMBRIDGE, MA -- Measuring the density of a cell can reveal a great deal about the cell’s state. As cells proliferate, differentiate, or undergo cell death, they may gain or lose water and other molecules, which is revealed by changes in density.
Tracking these tiny changes in cells’ physical state is difficult to do at a large scale, especially with single-cell resolution, but a team of MIT researchers has now found a way to measure cell density quickly and accurately — measuring up to 30,000 cells in a single hour.
The researchers also showed that density ...
Mask users can now breathe easy on two counts
2025-05-20
Tokyo, Japan—The COVID-19 pandemic increased public awareness of the importance of mask use for personal protection. However, when the mesh size of mask fabrics is small enough to capture viruses, which are usually around one hundred nanometers in size, the fabric typically also restricts air flow, resulting in user discomfort. But now, researchers from Japan have found a way to avoid this.
In a study published this month in Materials Advances, researchers from the Institute of Industrial Science, The University of Tokyo have overcome this bottleneck and developed a filter capable of capturing nanoparticles such ...
Aging reduces CAR-T cell effectiveness by impairing metabolism, study shows
2025-05-20
As people age, their immune systems become less efficient, posing a challenge for cancer therapies that rely on harnessing immune cells. In a new study published in Nature Cancer, researchers from the University of Lausanne (UNIL), the Lausanne University Hospital (CHUV), the Geneva University Hospitals (HUG) and the Ecole Polytechnique Fédérale de Lausanne (EPFL), show that this age-related immune decline has a measurable impact on CAR-T cell therapy, one of the most advanced forms of cancer immunotherapy.
CAR-T ...
Why are patients with mitochondrial disease more susceptible to infections? New JAX study finds the answer
2025-05-20
Patients with rare mitochondrial diseases already face a host of serious health issues, from muscle weakness to neurological problems and heart conditions. But one of their most life-threatening challenges has remained a mystery—why are they so vulnerable to severe infections?
Now, scientists at The Jackson Laboratory (JAX) may have finally pinpointed why. Their new study, published in Nature Communications, shows that damaged mitochondria put the immune system in a constant state of alert, leading to dangerous overreactions when patients encounter bacteria. This excessive immune ...